Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Long-Term Deferred Tax (2022 - 2026)

Gyre Therapeutics has reported Long-Term Deferred Tax over the past 4 years, most recently at $6.9 million for Q4 2025.

  • Quarterly Long-Term Deferred Tax rose 22.32% to $6.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $6.9 million through Dec 2025, up 22.32% year-over-year, with the annual reading at $6.9 million for FY2025, 22.32% up from the prior year.
  • Long-Term Deferred Tax was $6.9 million for Q4 2025 at Gyre Therapeutics, up from $6.7 million in the prior quarter.
  • Over five years, Long-Term Deferred Tax peaked at $6.9 million in Q4 2025 and troughed at $4.1 million in Q4 2022.
  • The 4-year median for Long-Term Deferred Tax is $5.4 million (2024), against an average of $5.5 million.
  • Year-over-year, Long-Term Deferred Tax rose 15.05% in 2023 and then skyrocketed 30.09% in 2025.
  • A 4-year view of Long-Term Deferred Tax shows it stood at $4.1 million in 2022, then increased by 15.05% to $4.7 million in 2023, then increased by 19.68% to $5.6 million in 2024, then increased by 22.32% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Long-Term Deferred Tax are $6.9 million (Q4 2025), $6.7 million (Q3 2025), and $6.1 million (Q2 2025).